Abstract OBJECTIVE: The cytochrome P450 subfamily IIIA5 (CYP3A5) gene is responsible for the metabolism of many clinically used anticancer agents. So far the studies on CYP3A5 gene has only been focused on the leukemia cell lines. This study examined the polymorphism of CYP3A5 and tried to find the possible relationship between CYP3A5 gene expression and treatment outcome or prognosis in children with acute leukemia. METHODS: The genotype distribution of CYP3A5-6986A/G gene polymorphism was detected with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 66 children with newly diagnosed acute leukemia (AL) and 22 control individuals. Quantitative real-time RT-PCR was used to examine wt-CYP3A5 and SV1-CYP3A5 mRNA levels in the bone marrow. RESULTS: Three genotypes of CYP3A5-6986A/G polymorphisms were found: CYP3A5*1/*1, CYP3A5*1/*3 and CYP3A5*3/*3. There were significant differences in the wt-CYP3A5 mRNA expression among the AL patients with different genotypes (P<0.05). In patients with acute lymphocytic leukaemia (ALL), the complete remission (CR) rate in the group with a low expression of wt-CYP3A5 mRNA was significantly higher than that in the group with a high expression (P<0.05). A dynamic monitoring for wt-CYP3A5 mRNA expression was performed in two cases of ALL. The expression increased before ALL relapse compared with that in CR in a patient, while in the other patient, the expression was kept in a low level and the patient remained in CR CONCLUSIONS: wt-CYP3A5 mRNA expression was associated with the treatment outcome and prognosis in children with AL. Dynamic monitoring for wt-CYP3A5 mRNA expression in the bone marrow may be useful in the evaluation of the disease severity in childhood acute leukemia.［Chin J Contemp Pediatr, 2009, 11 (7):549-554］
［2］Mitra R, Srirangam A, Capdevila J, Potter DA. Cytochrome P450 promotes breast cancer cell proliferation［J］.Proc Amer Assoc Cancer Res, 2006, 47(4):1220-1221.
［3］Janardan SK, Lown KS, SchmiedliRen P,Thummel KE,Watkins PB.Selective expression of CYP3A5 and not CYP3A4 in human blood［J］. Pharmacogenetics,1996, 6(5):379-385.
［4］Asghar A, Gorski JC, Haehner-Daniels B, Hall SD. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin［J］. Drug Metabolism Disposition, 2002, 30(1):20-26.
［5］Furukawa M, Nishimura M, Ogino D, Chiba R, Ikai I, Ueda N. Cytochrome P450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver［J］. Cancer Sci, 2004, 95（6）:520-529.
［6］Nagai F, Hiyoshi Y, Sugimachi K, Tamura HO. Cytochrome P450(CYP450) expression in human myeloblastic and lymphoid cell lines［J］.Bio Pharm Bull, 2002, 25(3):383-385.
［7］Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intdstinal midazolam metabolism［J］. Mol Pharmacol, 2002, 62(1):162-172.
［8］Lee SJ, Jusko WJ, Salaita CG, Calis KA, Jann MW, Spratlin VE, et al. Redued methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition［J］.J Clin Pharmacol, 2006, 46(5)：515-526.
［9］Smith NF, Figg WD, Sparreboom A. Recent advances in pharmacogenetic approaches to anticancer drug development［J］.Drug Devel Res, 2004, 62(3): 233-253.
［10］Pakakasama S, Mukda E, Sasanakul W, Kadegasem P, Udomsubpayakul ,Thithapandha A, Hongeng S. Polymorphisms of drug metabolizing enzymes and risk of childhood acute lymphoblastic leukemia ［J］.Am J Hematol, 2005, 79(3):202-205.
［11］Liu TX, Zhang JW, Tao J, Zhang RB, Zhang QH, Zhao CJ, et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells［J］. Blood, 2000, 96(4):1496-1504.
［12］Ikezoe T, Daar ES, Hisatake J, Taguchi H, Koeffler HP. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells［J］.Blood, 2000, 96（10）:3553-3559.
［13］Lu H, Waxman DJ. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism［J］. Mol Pharmacol, 2005, 67(1):212-219.
［14］Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies［J］. J Clin Oncol, 2002, 20(1):3683-3690.
［15］Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, et al. Effects of prednisone and genetic polymorphisms on etoposide diposition in children with acute lymphoblastic leukemia［J］. Blood, 2004, 103(1):67-72.
